Deep search
Search
Images
Videos
Maps
News
Shopping
Copilot
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs between 2017 and 2022,
Report: 'Pharmacy Benefit Managers' profited billions by raising prices of 'specialty drugs'
The Pharmaceutical Care Management Association, which represents PBM's, called the FTC report baseless and "without substantiating evidence."
Top three insurers reaped $7.3 billion through their drug middlemen's markups, FTC says
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" prescription price hikes of 1,000% or more.
PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through
FTC: Big 3 PBMs generated $7.3B from specialty generic drug markups
CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal Trade Commission (FTC) uncovered in its second interim staff report rele | The FTC released its second interim staff report Tuesday during Chair Lina Khan's final open commission meeting,
FTC Report Reveals PBM Practices Impacting Competition and Drug Costs
The FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty generic drugs,
FTC takes fresh swipe at drug middlemen, says some prices marked up over 1,000%
The drug middlemen known as pharmacy-benefit managers took another body blow from regulators on Tuesday, as they were criticized for charging way more for some “critical” prescription drugs than it cost them.
Largest Pharmacy-Benefit Managers Hiked Up Drug Prices, FTC Says
The largest pharmacy-benefit managers hiked the prices of certain drugs dispensed through their own pharmacies, according to a new report by the Federal Trade Commission released on Tuesday. The markups helped the PBMs reap $7.
FTC releases second report on PBM price hikes of specialty drugs
The FTC released a 60-page report Tuesday targeting the biggest three pharmacy benefit managers, claiming the companies hiked the prices of specialty drugs to generate $7.3 billion in revenue from 2017 to 2022.
FTC says ‘Big 3 PBMs’ marked up generic drugs by thousands of percent
The Federal Trade Commission published a second interim staff report on the prescription drug middleman industry, which it says focuses on
PBMs Generated Billions in Drug Markups, FTC Says
Major pharmacy-benefit managers generated $7.3 billion in markups on specialty drugs from pharmacies they are affiliated with, the FTC said in a new report.
STAT
23h
Will PBM reform save pharmacies from closing?
Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
15h
FTC Launches Inquiry of Single-Family Rental Home 'Mega Investors,' Issues PBM Report
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
pharmaphorum
20h
FTC doubles down on PBM criticism in new report
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
Fierce Healthcare
2d
Industry Voices—Why the great unraveling of PBMs will accelerate in 2025
The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...
13d
The PBM Bill Failed: Implications For PBM Reform
The time is right for PBM reform, but the American people might be better served if Congress goes back to the drawing board ...
14h
on MSN
UnitedHealth, employer of slain exec Brian Thompson, found to have overcharged some cancer patients for drugs by over 1,000%
CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...
penncapital-star
3h
Regulator accuses drug middlemen of wild price hikes, possibly steering business to themselves
The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for ...
Benefits Pro
1d
Sen. Warren brings bipartisan team back for more action against PBMs
The Massachusetts Democrat is working with a Missouri Republican, and House members from each party, to press the FTC to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
FTC report
Massachusetts
Pharmacy benefit management
Federal Trade Commission
UnitedHealth Group
Feedback